Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.
Boissier E, Mir O, Hollebecque A, Izzedine H, Ederhy S, Gazzah A, Bahleda R, Massard C, Macquin-Mavier I, Tournigand C, Spano JP, Soria JC, Rousseau B.
Boissier E, et al. Among authors: macquin mavier i.
Invest New Drugs. 2017 Feb;35(1):79-86. doi: 10.1007/s10637-016-0402-3. Epub 2016 Oct 25.
Invest New Drugs. 2017.
PMID: 27783256